Citigroup upgraded shares of Calithera Biosciences (NASDAQ:CALA) from a neutral rating to a buy rating in a research note issued to investors on Friday, MarketBeat reports. Citigroup currently has $14.00 target price on the biotechnology company’s stock, up from their previous target price of $6.95.
Other analysts have also recently issued research reports about the company. Zacks Investment Research cut Calithera Biosciences from a buy rating to a hold rating in a research report on Tuesday, January 2nd. ValuEngine cut Calithera Biosciences from a sell rating to a strong sell rating in a report on Saturday, February 3rd. Finally, BidaskClub cut Calithera Biosciences from a sell rating to a strong sell rating in a report on Thursday, January 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $16.67.
Shares of Calithera Biosciences (NASDAQ CALA) opened at $8.10 on Friday. Calithera Biosciences has a 1 year low of $6.57 and a 1 year high of $20.05. The stock has a market capitalization of $287.36, a PE ratio of -8.18 and a beta of 2.56.
ILLEGAL ACTIVITY NOTICE: “Calithera Biosciences (CALA) Lifted to “Buy” at Citigroup” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/20/calithera-biosciences-cala-lifted-to-buy-at-citigroup.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.